A war of words between Allergan (AGN) and a big hedge fund escalated after the drug maker agreed to support a shareholder proposal to eventually split the roles of chairman and chief executive, a move that Appaloosa called a “vague” and “lame attempt” at deflecting investor pressure.

Moreover, the fund also challenged the board to consider a merger or sale, “if is unable or unwilling to hold management accountable for its shortcomings or find a suitable replacement” for the Allergan team led by chief executive Brent Saunders.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy